ID: ALA5209077

Max Phase: Preclinical

Molecular Formula: C42H55N7O5

Molecular Weight: 737.95

Associated Items:

Representations

Canonical SMILES:  CN(C(=O)C1CCN(C(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](CCc2ccccc2)C(=O)N[C@@H]2CCCc3ccccc32)CC1)c1cccnc1

Standard InChI:  InChI=1S/C42H55N7O5/c1-42(2,3)28-44-37(50)26-36(47-41(54)49-24-21-31(22-25-49)40(53)48(4)32-16-11-23-43-27-32)39(52)46-35(20-19-29-12-6-5-7-13-29)38(51)45-34-18-10-15-30-14-8-9-17-33(30)34/h5-9,11-14,16-17,23,27,31,34-36H,10,15,18-22,24-26,28H2,1-4H3,(H,44,50)(H,45,51)(H,46,52)(H,47,54)/t34-,35+,36+/m1/s1

Standard InChI Key:  QKDPSYPADGGOQK-SBPNQFBHSA-N

Associated Targets(Human)

20S proteasome 530 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RPMI-8226 44974 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MM1.S 1111 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MV4-11 7307 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 737.95Molecular Weight (Monoisotopic): 737.4265AlogP: 4.70#Rotatable Bonds: 13
Polar Surface Area: 152.84Molecular Species: NEUTRALHBA: 6HBD: 4
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.56CX Basic pKa: 4.34CX LogP: 3.60CX LogD: 3.60
Aromatic Rings: 3Heavy Atoms: 54QED Weighted: 0.20Np Likeness Score: -1.00

References

1. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source